---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-020803"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2023-06-12T23:59:59+00:00"
generated_at: "2026-06-14T03:15:03.525112+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ZyVersa receives Nasdaq delisting notice for $1.00 bid price non-compliance

## Summary
- Received Nasdaq notice on June 9, 2023 for failing to maintain $1.00 minimum bid price over 30 consecutive business days.
- Has 180 calendar days, until December 6, 2023, to regain compliance by closing at or above $1.00 for 10 consecutive business days.
- If not cured, may seek a second 180-day period if it meets other listing standards and notifies intent to cure.
- Failure to regain compliance could lead to delisting; company may appeal to Nasdaq hearings panel.
- Company states there is no assurance it will regain compliance or secure an extension.

## SEC filing metadata
- accession: 0001493152-23-020803
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2023-06-12T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315223020803/0001493152-23-020803-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315223020803/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-020803
- JSON: https://secwatch.observer/filing/0001493152-23-020803.json
- Plain text: https://secwatch.observer/filing/0001493152-23-020803.txt

## Key facts
- Listing & Compliance Notices
  ZyVersa Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: June 9, 2023, ZyVersa Therapeutics, Inc. (the “ Company ”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Notice ”). The Notice has no immediate effect on
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315223020803/0001493152-23-020803-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.